recently reported that the processing of APP by the presenilin/g-secretase complex to release the APP intracellular domain (AICD) allows the latter to upregulate the cellular expression of neprilysin. The authors emphasized the biological elegance of this novel feedback mechanism in that a by-product (AICD) of thegeneration of amyloid b protein (Ab) increases the levels of a protease (neprilysin) that can then degrade Ab. Here, we report that experiments similar to those of Pardossi-Piquard et al. did not provide evidence that neprilysin levels and activity are regulated by presenilin-mediated processing of APP.
Results

Neprilysin Protein Levels Do Not Correlate with Presenilin Genotype and Are Not Rescued by Presenilin Expression
To examine whether neprilysin protein levels are regulated by presenilin (PS) expression as reported (PardossiPiquard et al., 2005) , mouse embryonic stem cells genetically devoid of both PS1 and PS2 (BD8 cells) were analyzed by Western blotting (see Methods in the Supplemental Data available online). Cells were harvested in Tris buffer containing either no detergent, 0.5% Triton X-100, or 1% NP40 and blotted for neprilysin, APP C-terminal fragments (CTFs), and GAPDH. The lack of PS expression resulted in no significant reduction in neprilysin levels in cells harvested in either Tris buffer or Tris-1% NP40 buffer compared to identically prepared wt embryonic stem cells (PBD8) ( Figure 1A ). In cells harvested in Tris-0.5% Triton buffer, we observed either a modest (Figure 1A) or no ( Figure S1A ) reduction in neprilysin levels. To determine whether introduction of presenilin could rescue this variable and modest decrease, the BD8 cells were transiently transfected with PS1, PS2, or both. Transfection of PS resulted in the rescue of g-secretase complex formation (PS endoproteolysis and enhanced nicastrin maturation) and activity (reduction in the elevated APP CTFs) in the BD8 cells ( Figure 1B) (Chen et al., 2003; Kimberly et al., 2002; Leem et al., 2002) . However, neprilysin levels were unchanged ( Figure 1B ). When quantified, neprilysin levels (versus control) were 93.7% ± 0.2% (SEM), 105.7% ± 1.1%, and 98.6% ± 18.3% for cells transfected with PS1, PS2, or both, respectively (p > 0.05 in all cases) ( Figure S1B ).
Next, we examined primary mouse embryonic fibroblasts (MEFs) cultured from mice genetically lacking PS1, PS2, or both, using the same source as those analyzed by Pardossi-Piquard et al. (Herreman et al., 2003) . Neprilysin levels were reduced in PS dKO cells as compared to wt ( Figure 1C ). Because PS1 confers the predominant PS activity found in g-secretase, it would be expected that PS1 KO cells would have dramatically reduced g-secretase activity. Moreover, no mature nicastrin was detected, and APP CTF levels were elevated in PS1 KO cells, similar to what occurred in PS dKO cells. Nevertheless, PS1 KO cells displayed the highest levels of neprilysin ( Figure 1C) , suggesting that the variable levels of neprilysin among these MEF lines is independent of PS/g-secretase function but may be due to clonal variation. To further determine whether the reduction of neprilysin levels in PS dKO MEFs is due to the absence of PS, we transiently transfected cells with PS1 and analyzed neprilysin levels. Introduction of PS1 was able to rescue g-secretase complex formation and activity, but neprilysin levels were unchanged ( Figure 1D ). Quantification of two independent experiments (each with n = 6) revealed that PS1-transfected cells had neprilysin levels that were 105.5% ± 3.6% (SEM) of control cells ( Figure S1C ). Together, these data suggest that the presence or absence of PS expression does not affect neprilysin levels in the examined blastocytes and primary fibroblasts.
g-Secretase Inhibition Does Not Reduce Neprilysin Protein Levels
To examine whether neprilysin levels are regulated by g-secretase activity, wt mouse embryonic stem cells (PBD8) and 293T cells were treated for 48 hr with serial applications of a potent and well-characterized (Seiffert et al., 2000) g-secretase inhibitor, compound E. In the PBD8 cells, we were able to detect the endogenous AICD fragment of APP and saw its disappearance with compound E, along with a rise in APP CTFs (Figure 2A ). But even with this prolonged and effective inhibition of g-secretase, we observed no decrease in neprilysin levels in both cell lines (Figure 2A) . Quantification of neprilysin protein levels revealed no significant difference between control and compound E-treated cells ( Figure 2B ). Compound E-treated samples were 94.3% ± 6.1% (SEM) and 107.9% ± 3.7% of vehicle-treated samples for PBD8 and 293T cells, respectively. In addition, we observed no changes in neprilysin levels with single acute treatments of compound E in PBD8 and 293T cells ( Figure S2 ).
Next, we examined prolonged gsecretase inhibition in wt MEFs. Treatment with DAPT (Dovey et al., 2001) , another well-characterized g-secretase inhibitor used by PardossiPiquard et al., increased APP CTF levels as expected but did not reduce neprilysin levels ( Figure 2C ). DAPT-treated cells had 117.2% ± 6.2% of neprilysin levels versus controls (p > 0.05) (Figure 2D) . Thus, cellular neprilysin levels were unaffected by two distinct g-secretase inhibitors. Neprilysin Levels Are Not Altered by Introduction of the Putative Transcriptional Complex of AICD, Fe65, and Tip60 To determine whether a transcriptional complex consisting of AICD, Fe65, and Tip60 (Cao and Sudhof, 2001 ) can regulate the transcription and thus the levels of neprilysin, as reported (Pardossi-Piquard et al., 2005) , BD8 cells lacking PS1 and PS2 were transiently transfected with an AICD-like construct (C60) along with the adaptor protein Fe65 and the histone acetyltransferase Tip60. Levels of neprilysin, C60, Fe65, and Tip60 were analyzed by Western blotting at 24 and 48 hr. Fe65 and Tip60 expression levels were substantial at 24 hr and much lower at 48 hr ( Figure 3A ). The coexpression of Fe65 and Tip60 with C60 resulted in a stabilization of C60 ( Figure 3A ), as reported (Kimberly et al., 2001) . Nevertheless, neprilysin protein levels did not increase significantly upon cointroduction of C60, Fe65, and Tip60 at either 24 or 48 hr.
Next, we searched for C60/Fe65/ Tip60-mediated regulation of neprilysin in wt PBD8 mouse embryonic stem cells and wt 293T cells. Consistent with the above results in the PS-deficient BD8 cells, neprilysin levels were unchanged upon transfection with C60, Fe65, and Tip60 in both PBD8 ( Figure 3B ) and 293T cells ( Figure 3C ). In the 293T cells, coexpression of all three proteins produced a particularly robust stabilization of C60 levels (Figure 3C, last two lanes) , and yet there was no change in neprilysin levels, in direct contrast to the results of Pardossi-Piquard et al. (2005) . These data indicate that neprilysin protein levels are not regulated by a putative transcriptional complex of C60, Fe65, and Tip60 in the examined cell lines. Neprilysin Levels and Activity Are Not Affected by Lack of APP or APLP-2 In Vivo To examine whether APP and APLP-2 are involved in the regulation of neprilysin levels in vivo as reported (PardossiPiquard et al., 2005) , brain homogenates from APP À/À or APLP-2 À/À mice were analyzed by both a neprilysin activity assay and Western blotting. Activity was measured by hydrolysis of the well-established fluorogenic enkephalin-based substrate, N-Dansyl-D-AlaGly-p-nitro-Phe-Gly (Florentin et al., 1984) . Activity corresponding to neprilysin was determined by phosphoramidon sensitivity, as used by PardossiPiquard et al. (2005) . Importantly, our assay provided a specific measure of neprilysin activity, as we detected essentially no activity in brain homogenates from neprilysin knockout mice ( Figure  4A, insert) . A time course measuring neprilysin activity over 40 hr yielded no significant difference between wt and APP À/À or APLP-2 À/À brains ( Figure 4A ). We performed additional measurements of neprilysin activity at the 8 hr time point and again found no difference between wt and knockout samples ( Figure 4B ). Neprilysin activities in APP À/À and APLP-2 À/À knockout brain homogenates were 95.3% ± 2.3% and 93.5% ± 4.2% (SEM) of wt. Consistent with these activity assays, neprilysin protein levels were indistinguishable between wt, APP À/À , and APLP-2 À/À homogenates (Figure 4C ). These data suggest that complete lack of APP or APLP-2 in mice reduces neither neprilysin activity nor protein levels in vivo. Finally, to determine whether partial inhibition of APP signaling alters neprilysin levels, Mint-1 (X11a) and Mint-2 (X11b), which have been found to inhibit an APP-dependent transactivation assay (Biederer et al., 2002) , were transfected into both PBD8 and 293T cells. In contrast to the results of Pardossi-Piquard et al., confirmed overexpression of Mint-1 or Mint-2 did not reduce neprilysin levels ( Figure 4D ).
Discussion
We obtained no evidence that neprilysin levels or activity are significantly regulated by PS-mediated processing of APP to AICD. We assessed neprilysin protein levels in the same PS1/ PS2-deficient mouse blastocyte and fibroblast lines (BD8 [Hass and Yankner, 2005; Zhang et al., 2000] ; MEFs [Herreman et al., 2003 ]) used by Pardossi-Piquard et al. but found no significant decrease. Instead, we found substantial clonal variability in neprilysin levels that did not correlate with presenilin genotype. Neprilysin levels in wt mouse embryonic stem cells, fibroblasts, and HEK293T cells were unchanged by a g-secretase inhibitor. Moreover, transfection of wt mouse embryonic stem cells or 293T cells with AICD alone; Fe65 plus Tip60 alone; or AICD, Fe65, and Tip 60 together produced no change in cellular neprilysin levels. Finally, phosphoramidon-sensitive neprilysin activity in mouse brains entirely lacking APP or APLP-2 was indistinguishable from that in wt brains. We believe that technical differences are unlikely to explain the fundamental discrepancies between the two studies.
In addition to this lack of experimental confirmation, theoretical considerations make such a mechanism improbable. First, neprilysin has numerous high-affinity substrates in many tissues, including Leu-enkephalin and bradykinin (reviewed in Welches et al., 1993) . Therefore, an APP-centered mechanism to upregulate neprilysin would enhance degradation of not only Ab but other biologically important peptides as well. APP and PS/g-secretase are expressed ubiquitously, so that AICD is generated in virtually all cell types, whereas Ab is made primarily in the brain, where bsecretase levels are high. In the many tissues that undergo little Ab generation, the specific feedback mechanism of Pardossi-Piquard et al. would not be required. Second, in all organs besides the brain, the vast majority of APP, APLP-1, and APLP-2 molecules undergo intramembrane proteolysis by g-secretase as the result of an initial cleavage by a-secretase, not b-secretase. Therefore, most AICD production in organisms occurs from flux through the a-secretase pathway without yielding Ab. Indeed, a-secretase can be physiologically upregulated by numerous signaling pathways in both nonneural and neural cells, e.g., via activation of the phospholipase C/protein kinase C pathway (Buxbaum et al., 1993; Hung et al., 1993) , and the more such a-secretase processing of APP occurs, the more AICD is produced but the less Ab is generated. Thus, it seems counterintuitive that AICD, the generation of which generally precludes Ab production, would then stimulate neprilysin expression to further lower Ab. Third, most mammals (e.g., mice and rats) show no detectable accumulation of Ab throughout life, making it unlikely that there would have been evolutionary pressure for a specific mechanism to upregulate the neprilysin cleavage of Ab. These various concerns about biological plausibility, together with the lack of experimental support from our study, make this mechanism untenable at present.
Supplemental Data
The Supplemental Data for this article can be found online at http://www.neuron.org/cgi/ content/full/53/4/479/DC1/. We recently established that neprilysin (NEP), one of the putative amyloid b-peptide (Ab)-degrading enzymes, is transcriptionally upregulated by AICDs, the C-terminal fragments of the b-amyloid precursor protein (bAPP/APLP) that are generated by presenilin (PS)-dependent g-and 3-secretase activities (Pardossi-Piquard et al., 2005) . Chen and Selkoe now report lack of evidence of NEP upregulation by PS-dependent g-secretase. To explore the reasons for this difference, we have repeated several experiments, conducted new experiments, and carefully examined the data presented by Chen and Selkoe. These analyses reveal that (1) there is significant consensus in key experimental data; (2) several of Chen and Selkoe's negative conclusions are overreaching, arising from a crucial conceptual error on their part; and (3) there is compelling, independent data from experiments in nicastrin null cells and in brain from transgenic mice overexpressing AICD that support the notion that presenilin complexes and AICD modulate inducible NEP expression.
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Results and Discussion
There is consensus on several important points. Both groups find that NEP expression is dramatically reduced in PS1 À/À
:PS2
À/À double-knockout mouse embryonic fibroblasts (MEFs) (Figures 1D and 1E in Pardossi-Piquard et al., 2005; Figures 1A and 1B in this paper; Figure 1C in Chen and Selkoe, 2007) . Both groups find modest reductions (%25%) in NEP expression in PS1 À/À :PS2 À/À double-knockout BD8 blastocyst cells (Figures 1F and 1G in Pardossi-Piquard et al., 2005 ; Figure 1A in Chen and Selkoe, 2007 Chen and Selkoe, 2007) . Repetition of several of our experiments using different MEF cell lines and different anti-NEP antibodies reveals that the results are unchanged ( Figures 1A and 1B) . This argues against an artifact arising from laboratory error or from differences in clones. We have also pursued additional experiments, both of which strongly support the validity of our initial report.
First, we investigated NEP activity, protein, and mRNA levels in nicastrin knockout MEFs (NCT À/À ), which do not form functional presenilin complexes and which have no g-secretase activity (Yu et al., 2000) . NEP expression, NEP activity, and NEP mRNA levels were all dramatically reduced in nicastrin knockout MEFs (NCT À/À ) (Pardossi-Piquard et al., 2006) (Figure 1C) . However, NEP expression is restored in these NCT À/À MEFs by
